Latest research on Oxaliplatin

Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as Folfox for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity. The chlorine ligands are replaced by the oxalato bidentate derived from oxalic acid in order to improve water solubility. Oxaliplatin is marketed by Sanofi-Aventis under the trademark Eloxatin®.

Latest findings

After the year 2000, FOLFOX (Oxaliplatin plus 5-FU and LV) and FOLFIRI (Irinotecan plus 5-FU and LV) were developed and modified over the course of several years. [source, 2016]
A regimen combining the oral agent Capecitabine with Oxaliplatin (XELOX) was developed for the treatment of colorectal cancer. [source, 2016]
In patients with colorectal cancer in the FAS and PAS (n=153 and n=71, respectively), 5-Fluorouracil (5-FU) plus Oxaliplatin (14% in both populations), 5-FU plus Irinotecan (13% and 20%), Capecitabine plus Oxaliplatin (12% and 10%), and 5-FU plus Irinotecan plus bevacizumab (9% and 11%) were the most common “standard” regimens. [source, 2016]
Of the “non-standard” regimens used, 5-FU (18% in both populations), Irinotecan (12% and 13%), and Oxaliplatin (11% and 10%) were the most commonly used agents (for FAS and PAS, respectively). [source, 2016]
However, the usual dose of Cisplatin (300–450 mg/m2) and Oxaliplatin (≥700 mg/m2) were greatly different from each other. [source, 2016]
For the same reason, significant dose differences between the subgroups of Cisplatin and Oxaliplatin may not be adequately interpreted at face value (Table 3). [source, 2016]
Further research with larger numbers of patients comparing the dose for each chemotherapeutic agents (i.e., Cisplatin or Oxaliplatin) should be performed. [source, 2016]
Generally, valid assessments are 3-monthly clinical visits for the first three years, followed by 6-monthly visits for further two years with clinical examination, evaluation of long-term toxicities (polyneuropathy after Oxaliplatin), and CEA testing [4,98-100]. [source, 2016]
Her past medical history was significant for sigmoid adenocarcinoma status after low anterior resection and four cycles of FOLFOX chemotherapy (Leucovorin, 5-Fluorouracil, and Oxaliplatin) administered via a port-a-cath. [source, 2016]
Systemic chemotherapies for GEP-NET included Octreotide, VIP (vincristine, Ifosfamide, Cisplatin), XELOX (Capecitabine, Oxaliplatin), EP (Etoposide, Cisplatin), pazopanib, Sunitinib, everolimus, and XELIRI (Capecitabine, Irinotecan). [source, 2016]